Sort   by:  
 Page size 
ProteomicsOrganelle resolved proteomics reveals new chordoma cell surface markers required for proliferation and association with outcome
Here, we used a proteomics approach to identify novel chordoma-specific cell-surface protein markers. Four established chordoma cell lines (U-CH17P, U-CH17M, U-CH17S and U-CH11R) were analyzed by quantitative proteomics using a comprehensive organellar fractionation approach based on differential ul...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2022-03-31 | MSV000089171 | MassIVE
GenomicsWTCCC2 VL Brazil - samples
WTCCC2 Visceral Leishmaniasis samples from Brazil using Illumina 670k
EGAD00010000636 | EGA
GenomicsWTCCC2 VL Sduan - samples
WTCCC2 Visceral Leishmaniasis samples from Sudanl using Illumina 670k
EGAD00010000640 | EGA
GenomicsWTCCC2 VL India - samples
WTCCC2 Visceral Leishmaniasis samples from Indial using Illumina 670k
EGAD00010000638 | EGA
GenomicsWTCCC2 Visceral Leishmaniasis (VL) samples
A WTCCC2 project genome-wide association study for visceral leishmaniasis (VL) in individuals from India, Brazil and Sudan, genotyped on the custom Illumina 670k array. The WTCCC2 analysis of the Brazilian and Indian samples is described in Fakiola et al. [Nat Genet. 2013 Feb;45(2):208-13]. It shoul...
EGAS00001000773 | EGA
GenomicsWellcome Trust Case Control Consortium Data Access Committee
Access to summary data and individual-level genotype data is available by application to the Wellcome Trust Case Control Consortium Data Access Committee (CDAC). Access to data will be granted to qualified investigators for appropriate use. The CDAC also controls the individual level genotype data f...
EGAC00000000001 | EGA
UnknownA multinational Delphi consensus to end the COVID-19 public health threat.
Not available
S-EPMC9646517 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Not available
S-EPMC4835977 | biostudies-literature
Sort   by:  
 Page size